Nextech Invest
Venture capitalZurich · Seed–Late Stage · 41 people tracked
Also known as NEXTECH INVEST LTD.
Investment thesis
Nextech Invest concentrates on precision medicine, seeking and funding emerging biotechnology companies developing transformative cancer therapies. Operating from Zurich, the firm supports portfolio companies through pivotal stages of scientific validation and value creation, backing biotech innovators on a global scale.
Source: firm website, verified Aug 3, 2026.
Team · 41 people
from the firm's website & public directories
What they invest in
from 39 of 65 portfolio companiesBiotech ×38Medical Devices ×15Digital Health ×9Deep Tech ×7Healthtech ×7AI & Machine Learning ×4Data & Infrastructure ×1Developer Tools ×1
HQs:United States×28Canada×1
Investments · 65 tracked
founders shown can be your intro pathBiotechRedwood City, US
Laurence Lasky(Director)Alexis Borisy(Director)Margaret Horn(Executive Officer)Michael Bonney(Director)Mark A. Goldsmith(Executive Officer, Director)Elizabeth Anderson(Director)
Board seatThilo Schroeder· per SEC Form D · $56.4M raise · filed Jul 2018
Tango Therapeutics develops genetically targeted medicines using synthetic lethality principles to treat specific tumors.
BiotechBoston, US
John Ketchum(Director)Barbara Weber(Executive Officer, Director)Malte Peters(Director)Kanishka Pothula(Director)Lesley Ann Calhoun(Director)Mace Rothenberg(Director)
Board seatKanishka Pothula· per SEC Form D
Arvinas is a clinical-stage biopharmaceutical company developing PROTAC protein degrader therapies for oncology and neurology.
BiotechNew Haven, US
Stephen Squinto(Director)Liam Ratcliffe(Director)Andrew Levin(Director)Sean Cassidy(Executive Officer)Jonathan Soderstrom(Director)Brad Margus(Director)
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Benjamin Cravatt, Ph.D.(Director)Ho Sung Cho, Ph.D.(Director)Kristina Burow(Director)Carolyn Ng, Ph.D.(Director)Jakob Loven, Ph.D.(Director)Zachary D. Hornby(Executive Officer, Director)
C4 Therapeutics develops small molecule medicines called degraders that use targeted protein degradation (TPD) to eliminate disease-causing proteins via the body's ubiquitin proteasome system.
BiotechCambridge, US
Marc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)William M. Scalzulli(Director)Kenneth Anderson(Director)Malcolm S. Salter(Director)
BiotechPhiladelphia, US
Alex Levit(Executive Officer)Linda Beth West(Director)Martin Albert Lehr(Executive Officer, Director)Richard Jay Berman(Director)Philip Kantoff(Director)Jennifer Minai-Azary(Executive Officer)
Ideaya Biosciences develops precision medicines and targeted therapies for patients with hard-to-treat cancers and high unmet need.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Paul Stone(Executive Officer)Yujiro Hata(Executive Officer, Director)Timothy Shannon(Director)Terry Rosen(Director)Jeffrey Stein(Director)John Diekman(Director)
Kura Oncology is a company in the oncology/medtech sector that provides grant support for independent medical education programs designed to enhance healthcare professionals' ability to diagnose and treat patients in Kura Oncology's therapeutic areas of interest.
BiotechDigital HealthMedical DevicesLa Jolla, US
HEIDI HENSON(Executive Officer)TROY WILSON(Executive Officer, Director)ANNETTE NORTH(Executive Officer)PINGDA REN(Executive Officer)YI LIU(Executive Officer)ANTONIO GUALBERTO(Executive Officer)
Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.
BiotechDeep TechHealthtech
ORIC Pharmaceuticals is a clinical-stage oncology company founded in 2014 to develop cancer therapies that address treatment resistance, with the aim of extending the effectiveness of existing therapies.
BiotechHealthtechSouth San Francisco, US
Steve L. Hoerter(Director)Lori Kunkel(Director)Jacob M. Chacko(Executive Officer, Director)Richard Heyman(Chairman, Founder, Scientific Advisory Board)Dominic Piscitelli(Chief Financial Officer)Angie You(Director)
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
BiotechLondon
James Ede-Golightly(Director)Alistair Gray(Director)Craig Tooman(Executive Officer)Dave Lemus(Director)Giles Campion(Executive Officer)Romano Steven(Director)
BiotechCarlsbad, US
Robert More(Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Isan Chen, M.D.(Director)Daniel Bensen(Executive Officer)Nina Kjellson(Director)Alan Fuhrman(Executive Officer)
Zymeworks develops novel medicines for patients with difficult-to-treat diseases using proprietary platforms and in-house R&D capabilities.
BiotechDigital HealthMedical DevicesVancouver, US
HAIG FARRIS(Director)SHERMAINE TILLEY(Director)NOEL HALL(Director)Kenneth Galbraith(Director)inNICK BEDFORD(Director)GORDON NG(Executive Officer)
BiotechBurlingame, US
Alfred Scheidegger(Director)Mark Rolfe(Executive Officer)Peter Thompson(Director)Laura Shawver(Executive Officer, Director)Lewis Shuster(Director)Carol Gallagher(Director)
Board seatAlfred Scheidegger· per SEC Form D
Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.
AI & Machine LearningBiotechDeep TechPrinceton, US
Ben Cravatt(Scientific Founder)Phil Baran(Scientific Founder)Jin-Quan Yu(Scientific Founder)John Park(Executive Officer)John Clarke(Executive Officer, Director)
Board seatBenjamin Cravatt· per SEC Form D
A2 Biotherapeutics develops precision CAR T-cell therapies for people with cancer and other diseases using its Tmod cell engineering platform for autologous and allogeneic applications.
BiotechHealthtechAgoura Hills, US
Scott Foraker(Executive Officer, Director)Srini Akkaraju(Director)Madhavan Balachandran(Director)Michael Gallo(Director)David Goeddel(Director)C. Alexander Kamb(Director)
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Alterome is a clinical-stage precision oncology company developing small molecule therapies targeting mutant KRAS and AKT E17K in cancers including non-small cell lung, pancreatic, colorectal, endometrial, and breast cancer.
BiotechHealthtechMedical DevicesSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Thilo Schroeder(Director)Ryan B. Corcoran(Director, Promoter)Carl Gordon(Director)Arjun Goyal(Director)
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Peter Dudek(Director)
Arrakis Therapeutics discovers and develops RNA-targeted small-molecule drugs, a new drug modality that acts directly on RNA to treat diseases previously inaccessible to genetic medicine.
AI & Machine LearningBiotechDeep TechCambridge, US
Colleen Cuffaro(Director)Michael Gilman(Executive Officer, Director)Carolyn Green(Director)Alan E. Walts(Director)David Neafus(Executive Officer)Raj Parekh(Director)
Attovia develops precision biologics using its ATTOBODY platform for patients with immune-mediated diseases.
BiotechDigital Health
BiotechSan Mateo, US
Gina Chapman(Executive Officer, Director)Abraham Bassan(Director)Cassandra Gianna Luca(Director)Jeffrey Walsh(Director)Krishnan Viswanadhan(Director)Crystal Mackall(Director)
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)David J. Earp(President & CEO)Paul Park(Executive Officer)Scott R. Lokey(Director)Douglas Crawford(Director)Walter Moos(Director)
Exo Therapeutics is a small molecule drug discovery company developing therapeutics through its ExoSight platform, which targets exosites—unique binding pockets on enzymes—to address previously undruggable diseases in oncology, inflammation, and other therapeutic areas.
BiotechDeep TechMedical Devices
David Liu, PhD(Founder)Alan Saghatelian, PhD(Co-Founder)David LiuAlan Saghetelian
Bristol Myers Squibb is a biopharmaceutical company that develops and delivers medicines across oncology, hematology, neuroscience, immunology, and cardiovascular disease areas.
BiotechHealthtechMedical DevicesNew York, US
BiotechNew York, US
David Chang(Director, Promoter)Helen Kim(Director)Sean Algeo(Executive Officer, Promoter)Jakob Loven(Director)Mark A. McCamish(Executive Officer, Director)Joshua Kazam(Director)
BiotechCambridge, US
Robert Tepper(Director)Kim C. Drapkin(Executive Officer)Anna L. Barry(Executive Officer)Richard Murray(Executive Officer, Director)Cary Pfeffer(Director)Robert Kamen(Director)
BiotechSan Diego, US
Stephen W. Kaldor(Executive Officer, Director, Promoter)Eric Murphy(Executive Officer, Director)Bret Zbar(Director)Carl Gordon(Director)Michael Rome(Director)
BiotechNew York, US
Rebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)John C. Martin, Ph.D.(Director)Norbert Bischofberger, Ph.D.(Executive Officer, Director)Arie S. Belldegrun, M.D.(Director)
BiotechCambridge, US
Richard Gaynor, M.D.(Executive Officer)Cary Pfeffer, M.D.(Director)Robert Kamen(Director)Eric Lander(Director)Robert Ang, M.D.(Executive Officer)Yasir Al-Wakeel(Executive Officer)
Nextop IO provides a mobile content delivery network with a client-side library for iOS and Android that routes traffic through optimized proxy servers, reducing latency, improving throughput, and lowering data and battery consumption for mobile applications connecting to backend services.
Data & InfrastructureDeveloper ToolsEnterprise Software
Brien Colwell(Founder/CEO)in
Peloton Therapeutics is a clinical-stage pharmaceutical company developing first-in-class small molecule medicines targeting HIF-2α for cancer and other life-threatening conditions, with initial focus on kidney cancer and VHL disease.
BiotechDigital HealthMedical Devices
BiotechBoston, US
Adam Friedman(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)Gary Glick(Executive Officer, Director)
A drug discovery company founded by an experienced medicinal chemistry team with expertise in successful pharmaceutical development and clinical advancement.
BiotechDeep TechMedical DevicesWilmington, US
Liangxing Wu(Executive Officer, Director)Reid Huber(Director)Ting Feng(Director)Wenqing Yao(Executive Officer, Director)
BiotechCambridge, US
Iain Dukes(Executive Officer, Director)William C. Shakespeare(Director)Michael Rome(Director)Carl Gordon(Director)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does Nextech Invest invest at?
- Nextech Invest invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What is Nextech Invest's typical check size?
- Nextech Invest typically writes checks of $648K – $3.2M.
- What sectors does Nextech Invest focus on?
- Nextech Invest focuses on Biotech, Healthtech, Medical Devices.
- Where is Nextech Invest located?
- Nextech Invest is headquartered in Zurich, CH.
Co-investors · 26
RA Capital invests in public and private healthcare and life science companies developing pharmaceuticals, medical devices, and diagnostic tools. The firm operates as a crossover fund across multiple investment stages.
The Column Group (TCG) is a venture capital firm focused on building and backing biotechnology companies, applying an edge-to-edge investment model centered on company formation with capacity for long-term private and public capital support.
OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.
.jpeg)
Vida Ventures is a life sciences venture capital firm focused on transforming biomedical innovations into therapies that improve patients' lives.
ARCH Venture Partners is a venture capital firm that backs and helps build transformational companies, with a strong focus on the life sciences and biotech sector.
Canaan is an early-stage venture capital firm backing founders with transformative ideas across technology and healthcare.
Atlas Venture is a life sciences venture capital firm with three decades of experience investing in and building biotech and medical innovation companies, including startups launched from its own incubator.
Third Rock Ventures is a venture capital firm that discovers, launches, and builds life sciences and biotechnology companies developing novel medicines and therapies.
venBio is a life sciences venture capital firm that partners with industry leaders to develop novel therapeutics and technologies addressing unmet medical needs.
Andreessen Horowitz's Strategic Partnerships page describes collaborations that connect its portfolio companies with established institutions to help scale and deploy their technology.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
F-Prime Capital Partners is a venture capital firm whose team of scientists, engineers, physicians, operators, and investors supports companies in scaling and accelerating growth.
▶14 more co-investors
Samsara BioCapitalGeneral CatalystOUP (Osage University Partners)8VCVersant Ventures5AM VenturesNew Enterprise Associates (NEA)Lux CapitalSignalFireUS Venture PartnersTwo Sigma VenturesForbionFrazier Healthcare PartnersNew Leaf Venture Partners
Firms observed investing alongside Nextech Invest, from public investor directories. Shared companies are the overlap with Nextech Invest's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.